Payment overview · 2025
General Payments
$697.55
38 reported records · 16 companies
Healthcare provider profile · identity verified
Jonathan David Rowson, MD
Allopathic & Osteopathic Physicians|Family Medicine · LAURINBURG, NC · NPI 1194729830
Verified facts
What the public records show
CMS Open Payments records show Jonathan David Rowson, MD received $697.55 in general payments during 2025 across 38 reported records.
Ardelyx, Inc. accounted for 11.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $81.26 | 11.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $71.99 | 10.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $71.11 | 10.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $68.31 | 9.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $65.79 | 9.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.58 | 8.0% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $42.04 | 6.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $41.72 | 6.0% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $41.15 | 5.9% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $35.52 | 5.1% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $33.75 | 4.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.47 | 3.6% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $20.79 | 3.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.89 | 2.1% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $14.70 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.48 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $697.55 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $81.26 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $71.99 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $68.31 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $68.31 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.01 | 3 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $42.04 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $41.72 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $41.15 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.76 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $35.52 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $34.34 | 2 | 2025 |
Source payment records
|
|||||
| STRAVIX Normalized: stravix |
Biological | Smith+Nephew, Inc. | $33.75 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.25 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.03 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.03 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.47 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| GRAFIX Normalized: grafix |
Biological | Smith+Nephew, Inc. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 205 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 132 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 75 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 131 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
141 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
75 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
131 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
205 | 49 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 485 | 180 |
| Amlodipine Besylate | Amlodipine Besylate | 447 | 155 |
| Gabapentin | Gabapentin | 376 | 105 |
| Lisinopril | Lisinopril | 306 | 92 |
| Omeprazole | Omeprazole | 242 | 79 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 219 | 72 |
| Furosemide | Furosemide | 218 | 83 |
| Metformin Hcl | Metformin Hcl | 212 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 211 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 207 | 63 |
| Eliquis | Apixaban | 205 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 198 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 189 | 63 |
| Montelukast Sodium | Montelukast Sodium | 185 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 158 | 49 |
| Potassium Chloride | Potassium Chloride | 146 | 47 |
| Linzess | Linaclotide | 141 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 49 |
| Carvedilol | Carvedilol | 132 | 49 |
| Jardiance | Empagliflozin | 132 | 31 |
| Ozempic | Semaglutide | 131 | 32 |
| Trazodone Hcl | Trazodone Hcl | 127 | 31 |
| Allopurinol | Allopurinol | 122 | 38 |
| Simvastatin | Simvastatin | 122 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 55 |
| Famotidine | Famotidine | 110 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 32 |
| Metformin Hcl Er | Metformin Hcl | 104 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 33 |
| Losartan Potassium | Losartan Potassium | 98 | 43 |
| Celecoxib | Celecoxib | 95 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 94 | 31 |
| Prednisone | Prednisone | 93 | 55 |
| Tramadol Hcl | Tramadol Hcl | 88 | 30 |
| Alendronate Sodium | Alendronate Sodium | 86 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 26 |
| Sucralfate | Sucralfate | 79 | 27 |
| Mounjaro | Tirzepatide | 75 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 75 | 19 |
| Lovastatin | Lovastatin | 74 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 20 |
| Amoxicillin | Amoxicillin | 72 | 69 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 23 |
| Meclizine Hcl | Meclizine Hcl | 71 | 22 |
| Mirtazapine | Mirtazapine | 68 | 21 |
| Sertraline Hcl | Sertraline Hcl | 66 | 16 |
| Fluconazole | Fluconazole | 64 | 34 |
| Meloxicam | Meloxicam | 64 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 17 |
| Naproxen | Naproxen | 62 | 27 |
| Alprazolam | Alprazolam | 61 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | 21 |
| Ibuprofen | Ibuprofen | 59 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 36 |
| Lorazepam | Lorazepam | 56 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | 11 |
| Telmisartan | Telmisartan | 54 | 12 |
| Donepezil Hcl | Donepezil Hcl | 53 | 19 |
| Pregabalin | Pregabalin | 53 | 14 |
| Glimepiride | Glimepiride | 51 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 38 |
| Oxycodone Hcl | Oxycodone Hcl | 49 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 16 |
| Ezetimibe | Ezetimibe | 44 | suppressed |
| Spironolactone | Spironolactone | 44 | 19 |
| Levetiracetam | Levetiracetam | 42 | 13 |
| Benazepril Hcl | Benazepril Hcl | 41 | 13 |
| Nifedipine Er | Nifedipine | 41 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 41 | suppressed |
| Colchicine | Colchicine | 40 | 13 |
| Glipizide | Glipizide | 40 | 15 |
| Temazepam | Temazepam | 40 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 40 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | 15 |
| Ramipril | Ramipril | 39 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 38 | 12 |
| Buspirone Hcl | Buspirone Hcl | 37 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | 13 |
| Farxiga | Dapagliflozin Propanediol | 35 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 14 |
| Torsemide | Torsemide | 35 | 12 |
| Clonidine Hcl | Clonidine Hcl | 34 | 11 |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | 15 |
| Haloperidol | Haloperidol | 33 | 12 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 24 |
| Megestrol Acetate | Megestrol Acetate | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 16 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | 11 |
| Rybelsus | Semaglutide | 26 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 25 | 24 |
| Olanzapine | Olanzapine | 24 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 21 |
| Atenolol | Atenolol | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Febuxostat | Febuxostat | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | 11 |
| Ibu | Ibuprofen | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 11 |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 19 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Nystatin | Nystatin | 18 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 12 | 12 |
| Brilinta | Ticagrelor | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Repaglinide | Repaglinide | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $697.55 · 38 records | Ardelyx, Inc. | ABRYSVO, APTIMA, BREZTRI, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, GRAFIX, GRAFIX PL, IBSRELA, ISTURISA, JARDIANCE, Korlym, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, PREVNAR 20, Prolastin-C Liquid, QULIPTA, Rybelsus, STRAVIX, THINPREP 2000 PROCESSOR, UBRELVY, VOQUEZNA, Wegovy, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error